EUA
cobas SARS-CoV-2 & Influenza A/B
FDA Emergency Use Authorization · Roche Molecular Systems, Inc. · Feb 10, 2023
Key facts
| Product | cobas SARS-CoV-2 & Influenza A/B |
|---|---|
| Company | Roche Molecular Systems, Inc. |
| Product type | Real-time RT-PCR, Multi-analyte, Multiple Targets |
| Date | Feb 10, 2023 |
| FDA page | fda.gov |
At a glance
- 1–9 Authorization documents
- 1–9 EUAs for this company
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Emergency Use Authorizations
Emergency Use Authorizations allow the FDA to permit unapproved medical products, or unapproved uses of approved products, during a declared public health emergency.
Source: U.S. Food and Drug Administration (FDA), Emergency Use Authorizations · Source date: